Annual report
7129.TEDINET S100TX1I
Period2023-04-01 → 2024-03-31
Filed2024-06-28
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 99
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥22.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥22.2bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥19.5bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥395m | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Operating income | ¥191m | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Ordinary income | ¥374m | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥169m | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥190m | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥64m | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥348m | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥6m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥210m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥292m | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥6m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Net income | ¥210m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Total assets | ¥13.8bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥14.1bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥14.2bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥10.5bn | at 2024-03-31 | Cons. | Liabilities |
| Total liabilities | ¥10.8bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥3.3bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥3.3bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥3.2bn | at 2022-03-31d | Cons. | Net assets |
| Cash and deposits | ¥1.9bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.3bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.8bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.2bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.1bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.6bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.0bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥919m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥336m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥557m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.5bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥610m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥369m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥2.0bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥2.21 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥84.22 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥117.49 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥2.2 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥83.84 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥116.61 | 2021-04-01 → 2022-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥1,307.63 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,341.2 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,287.13 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 23.9% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 23.6% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 22.5% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 0.2% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.4% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 9.4% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 1,741 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 1,782 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 1,752 | at 2022-03-31d | Cons. | Number of employees |
| Revenue | ¥322m | 2023-04-01 → 2024-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥278m | 2022-04-01 → 2023-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥116m | 2021-04-01 → 2022-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥126m | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | ¥85m | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | ¥124m | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥90m | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥52m | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥124m | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥90m | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | ¥94m | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥60m | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥62m | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥3.2bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥3.2bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥3.1bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥107m | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥141m | at 2023-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥3.1bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥3.1bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥3.1bn | at 2022-03-31d | Standalone | Net assets |
| Cash and deposits | ¥57m | at 2024-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥32m | at 2023-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥37.73 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥24.16 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥24.86 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥37.51 | 2023-04-01 → 2024-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥24.06 | 2022-04-01 → 2023-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥24.68 | 2021-04-01 → 2022-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥30 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥30 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥17 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,230.31 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,226.96 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,232.94 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 96.6% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 95.6% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 97.7% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 3.1% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.0% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.0% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 2,527,300 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 2,488,700 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 2,488,300 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 92
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2023-04-01 → 2024-03-31 | ¥2m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2023-04-01 → 2024-03-31 | ¥3m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2024-03-31 | 18 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2024-03-31 | ¥972m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2024-03-31 | ¥929m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥42m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2024-03-31 | ¥146m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2024-03-31 | ¥28m |
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥6m |
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥36m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥42m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥42m |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥2.8bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥730m |
| Medicine Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥124m |
| Medicine Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥92m |
| Medicine Businessreportable segment | employees | at 2024-03-31 | 196 pure |
| Medicine Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥9.3bn |
| Medicine Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥9.3bn |
| Medicine Businessreportable segment | segment assets | at 2024-03-31 | ¥2.9bn |
| Medicine Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥545m |
| Nursing Care Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥79m |
| Nursing Care Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥42m |
| Nursing Care Businessreportable segment | employees | at 2024-03-31 | 300 pure |
| Nursing Care Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥3.3bn |
| Nursing Care Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥3.3bn |
| Nursing Care Businessreportable segment | segment assets | at 2024-03-31 | ¥909m |
| Nursing Care Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | −¥131m |
| Nurturing Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥84m |
| Nurturing Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥418m |
| Nurturing Businessreportable segment | employees | at 2024-03-31 | 1180 pure |
| Nurturing Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥9.2bn |
| Nurturing Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥9.2bn |
| Nurturing Businessreportable segment | segment assets | at 2024-03-31 | ¥7.0bn |
| Nurturing Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥684m |
| —segment total | capex | 2023-04-01 → 2024-03-31 | ¥287m |
| —segment total | depreciation | 2023-04-01 → 2024-03-31 | ¥551m |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥21.8bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥21.8bn |
| —segment total | segment assets | at 2024-03-31 | ¥10.9bn |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥1.1bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-04-01 → 2024-03-31 | ¥289m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-04-01 → 2024-03-31 | ¥555m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2024-03-31 | ¥22.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2024-03-31 | ¥22.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥42m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-03-31 | ¥11.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2024-03-31 | ¥1.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2022-04-01 → 2023-03-31 | ¥540,000 |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2022-04-01 → 2023-03-31 | ¥4m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2023-03-31 | ¥974m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2023-03-31 | ¥945m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥29m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2023-03-31 | ¥180m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2023-03-31 | ¥48m |
| Reconciling Itemsreconciling | capex | 2022-04-01 → 2023-03-31 | ¥13m |
| Reconciling Itemsreconciling | depreciation | 2022-04-01 → 2023-03-31 | ¥43m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥29m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥29m |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | ¥2.0bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥778m |
| Medicine Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥103m |
| Medicine Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥88m |
| Medicine Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥9.0bn |
| Medicine Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥9.0bn |
| Medicine Businessreportable segment | segment assets | at 2023-03-31 | ¥2.9bn |
| Medicine Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥531m |
| Nursing Care Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥8m |
| Nursing Care Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥45m |
| Nursing Care Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥3.4bn |
| Nursing Care Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥3.4bn |
| Nursing Care Businessreportable segment | segment assets | at 2023-03-31 | ¥1.1bn |
| Nursing Care Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | −¥147m |
| Nurturing Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥515m |
| Nurturing Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥400m |
| Nurturing Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥8.9bn |
| Nurturing Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥8.9bn |
| Nurturing Businessreportable segment | segment assets | at 2023-03-31 | ¥7.8bn |
| Nurturing Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥537m |
| —segment total | capex | 2022-04-01 → 2023-03-31 | ¥626m |
| —segment total | depreciation | 2022-04-01 → 2023-03-31 | ¥533m |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥21.3bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥21.3bn |
| —segment total | segment assets | at 2023-03-31 | ¥11.9bn |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥921m |
| Total Of Reportable Segments And Otherssegment total | capex | 2022-04-01 → 2023-03-31 | ¥626m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-04-01 → 2023-03-31 | ¥536m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2023-03-31 | ¥22.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2023-03-31 | ¥22.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥29m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-03-31 | ¥12.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2023-03-31 | ¥970m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,312
| Item | Context | Value | Unit |
|---|---|---|---|
| Career summary information about directors and corporate auditors (text) | FilingDateInstant_jpcrp030000-asr_E36714-000MinagawaTakashiMember | Text · Plus | |
| Term of office information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E36714-000MinagawaTakashiMember | Original text (Japanese)(注)３ | |
| Official title or position information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E36714-000AdachiMasahiroMember | Original text (Japanese)取締役（常勤監査等委員） | |
| Name information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E36714-000AdachiMasahiroMember | Original text (Japanese)足立 正弘 | |
| Date of birth information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E36714-000AdachiMasahiroMember | 1956-01-16 | |
| Career summary information about directors and corporate auditors (text) | FilingDateInstant_jpcrp030000-asr_E36714-000AdachiMasahiroMember | Text · Plus | |
| Term of office information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E36714-000AdachiMasahiroMember | Original text (Japanese)(注)４ | |
| Official title or position information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E36714-000ToyamaNorioMember | Original text (Japanese)取締役（監査等委員） | |
| Name information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E36714-000ToyamaNorioMember | Original text (Japanese)遠山 典夫 | |
| Date of birth information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E36714-000ToyamaNorioMember | 1964-03-23 | |
| Career summary information about directors and corporate auditors (text) | FilingDateInstant_jpcrp030000-asr_E36714-000ToyamaNorioMember | Text · Plus | |
| Term of office information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E36714-000ToyamaNorioMember | Original text (Japanese)(注)４ | |
| Official title or position information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E36714-000HaraMasaoMember | Original text (Japanese)取締役（監査等委員） | |
| Name information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E36714-000HaraMasaoMember | Original text (Japanese)原 正雄 | |
| Date of birth information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E36714-000HaraMasaoMember | 1973-11-30 | |
| Career summary information about directors and corporate auditors (text) | FilingDateInstant_jpcrp030000-asr_E36714-000HaraMasaoMember | Text · Plus | |
| Term of office information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E36714-000HaraMasaoMember | Original text (Japanese)(注)４ | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row2Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row3Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row4Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row5Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row6Member | Text · Plus | |
| Outside directors and outside corporate auditors (text) | FilingDateInstant | Text · Plus | |
| Audits (text) | FilingDateInstant | Text · Plus | |
| Note on change of independent auditors audits (text) | CurrentYearDuration | Text · Plus | |
| Remuneration for directors and other officers (text) | FilingDateInstant | Text · Plus | |
| Remuneration etc paid by group to each director or other officer (text) | FilingDateInstant | Text · Plus | |
| Shareholdings (text) | FilingDateInstant | Text · Plus | |
| Name of group company holding largest amount of investment shares in group | CurrentYearInstant | Original text (Japanese)ライフサポート株式会社 | |
| Reason for increase in number of shares shares not listed investment shares held for purposes other than pure investment largest holding company | CurrentYearDuration | － | |
| Reason for increase in number of shares shares other than those not listed investment shares held for purposes other than pure investment largest holding company | CurrentYearDuration | － | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYearDuration | Text · Plus | |
| Regulations in accordance with which financial statements have been prepared financial information | CurrentYearDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYearDuration | Text · Plus | |
| Remarkable efforts to ensure fair presentation of consolidated financial statements etc financial information | CurrentYearDuration | Text · Plus | |
| Consolidated balance sheet (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of income (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of comprehensive income (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of changes in equity (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of cash flows (text) | CurrentYearDuration | Text · Plus | |
| Notes significant accounting policies for preparation of consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Number of consolidated subsidiaries and names of major consolidated subsidiaries (text) | CurrentYearDuration | Text · Plus | |
| Changes in scope of consolidation (text) | CurrentYearDuration | Text · Plus | |
| Disclosure about fiscal years etc of consolidated subsidiaries (text) | CurrentYearDuration | Text · Plus | |
| Disclosure of accounting policies (text) | CurrentYearDuration | Text · Plus | |
| Significant accounting estimates consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding pledged assets (text) | CurrentYearInstant | Text · Plus | |
| Notes regarding accumulated depreciation of property plant and equipment (text) | CurrentYearInstant | Text · Plus | |
| Debtors notes regarding overdraft contracts and or loan commitments (text) | CurrentYearInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |